首页> 外文OA文献 >MP43-10 INVESTIGATION FOR INTRAVESICAL RECURRENCES BETWEEN WITH AND WITHOUT BCG THERAPIES ACCORDING TO HISTORY OF THERAPEUTIC AGENTS FOR DYSURIA IN NON-MUSCLE INVASIVE BLADDER CANCER

【2h】

MP43-10 INVESTIGATION FOR INTRAVESICAL RECURRENCES BETWEEN WITH AND WITHOUT BCG THERAPIES ACCORDING TO HISTORY OF THERAPEUTIC AGENTS FOR DYSURIA IN NON-MUSCLE INVASIVE BLADDER CANCER

机译：MP43-10根据非肌肉侵袭性膀胱癌的治疗剂历史和没有BCG疗法的术术复发的调查

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yoichiro Kato*; Daichi Kikuchi; Tomohiko Matuura; Renpei Kato; Mitsugu Kanehira; Ryo Takata; Jun Sugimura; Takaya Abe; Wataru Obara;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Dysuria therapeutic agents as an independent prognostic factor for the primary recurrence of non-muscle invasive bladder cancer: a propensity score matching study [J] . Yoichiro Kato, Daiki Ikarashi, Daichi Kikuchi, Journal of International Medical Research . 2021,第8期

机译：Dysuria治疗剂作为非肌肉侵袭性膀胱癌的主要复发的独立预后因素：倾向评分匹配研究
2. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guerin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy [J] . Progress in Artificial Intelligence . 2020,第1期

机译：I阶段的结果开放标签临床试验SAKK 06/14评估VPM1002BC的脑内滴注的安全性，重组分枝杆菌秃鹰植物蛋白（BCG），在非肌肉侵袭性膀胱癌的患者中，以前的常规BCG治疗失败
3. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guerin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy [J] . Cyrill A. Rentsch, Piet Bosshard, Gregoire Mayor, Oncoimmunology. . 2020,第1期

机译：I阶段的结果开放标签临床试验SAKK 06/14评估VPM1002BC的脑内滴注的安全性，重组分枝杆菌秃鹰植物蛋白（BCG），在非肌肉侵袭性膀胱癌的患者中，以前的常规BCG治疗失败
4. Improved temperature monitoring and treatment planning for loco-regional hyperthermia treatments of Non-Muscle Invasive Bladder Cancer (NMIBC) [C] . G. Schooneveldt, H.P. Kok, E.D. Geijsen World Congress on Medical Physics and Biomedical Engineering . 2015

机译：改善对非肌肉侵袭性膀胱癌（NMIBC）的基因群体热疗治疗的温度监测和治疗计划
5. Treatment patterns, costs and outcomes of systemic chemotherapy, adjuvant intravesical therapy, and surveillance for urothelial bladder cancer. [D] . Kerrigan, Matthew Charles. 2007

机译：全身化疗，辅助膀胱内治疗和尿路上皮膀胱癌监测的治疗方式，费用和结果。
6. Dysuria therapeutic agents as an independent prognostic factor forthe primary recurrence of non-muscle invasive bladder cancer: a propensity scorematching study [O] . Yoichiro Kato, Daiki Ikarashi, Daichi Kikuchi, 2021

机译：Dysuria治疗剂作为独立的预后因素非肌肉侵袭性膀胱癌的主要复发：倾向得分匹配研究
7. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy [O] . Cyrill A. Rentsch, Piet Bosshard, Grégoire Mayor, 2020

机译：I阶段开放标签临床试验SAKK 06/14评估VPM1002BC脑滴注的安全性，该重组分枝杆菌BacultusBudetteguérin（BCG），在非肌肉侵袭性膀胱癌患者中，以前的常规BCG治疗失败

MP43-10 INVESTIGATION FOR INTRAVESICAL RECURRENCES BETWEEN WITH AND WITHOUT BCG THERAPIES ACCORDING TO HISTORY OF THERAPEUTIC AGENTS FOR DYSURIA IN NON-MUSCLE INVASIVE BLADDER CANCER

著录项

引文网络

相似文献

相关主题

期刊订阅